Pharmaceuticals

Global Pneumococcal Vaccine Market 2026 projected to reach $12.76 billion by 2030

March 24, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Pneumococcal Vaccine Market Across 2026–2030?

The pneumococcal vaccine market has experienced robust expansion in recent times. Projections indicate it will expand from $9.4 billion in 2025 to reach $9.94 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. Historically, this growth is linked to factors such as a substantial burden of childhood pneumonia, the integration of these vaccines into national immunization programs, considerable backing from global health organizations, increased understanding of invasive pneumococcal disease, and the established effectiveness of PCV vaccines.

The pneumococcal vaccine market is projected to experience robust expansion over the forthcoming years. By 2030, this market is anticipated to reach a valuation of $12.76 billion, exhibiting a compound annual growth rate (CAGR) of 6.5%. This anticipated expansion during the forecast period is driven by several factors, including the introduction of advanced PCV vaccines, wider recommendations for adult vaccinations, improved access to healthcare services in developing nations, escalating worries regarding antimicrobial resistance, and governmental financial support for preventative immunization initiatives. Significant developments expected during this timeframe encompass the wider application of conjugate vaccines to cover more serotypes, heightened emphasis on immunization programs for children and the elderly, a greater uptake of vaccination strategies involving combinations and boosters, fortified collaborations between public and private sectors to enhance immunization reach, and an overall increase in preventive healthcare practices and national immunization plans.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Drivers Are Shaping The Future Growth Of The Pneumococcal Vaccine Market?

The increasing incidence of pneumococcal contamination is anticipated to drive the expansion of the pneumococcal vaccine market moving forward. Pneumococcal contamination refers to any infection caused by bacteria known as Streptococcus pneumoniae or pneumococcus, including ailments such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine stimulates the body’s production of antibodies against pneumococcal bacteria to diminish or eradicate disease-carrying bacteria and toxins, thereby protecting children, the elderly, and those with compromised immune systems from numerous types of pneumococcal infections. For example, in July 2025, the Immunisation Coalition, an independent not-for-profit charity based in Australia, reported that cases of invasive pneumococcal disease (IPD) have steadily risen each year, increasing from 1,869 in 2022 to 2,265 in 2023, and reaching 2,379 in 2024. Thus, the growing prevalence of pneumococcal contamination is a key driver for the growth of the pneumococcal vaccine market.

What Segmentation Levels Are Considered In The Pneumococcal Vaccine Market?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Trends Are Projected To Affect The Pneumococcal Vaccine Market?

Leading companies active in the pneumococcal vaccine market are innovating new products to boost their market profitability. For instance, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company, introduced its V116 vaccine. V116 is engineered to target the eight distinct serotypes of Streptococcus pneumoniae that are the primary cause of adult pneumococcal disease. In comparison to other pneumococcal vaccines, V116 has exhibited enhanced immunogenicity for a range of serotypes within adult populations, and it has also generated positive immune responses in both vaccine-naïve and previously vaccinated individuals. The U.S. Food and Drug Administration (FDA) has recognized V116 as a breakthrough therapy, and it is presently in Phase 3 development.

Which Leading Firms Are Contributing To The Growth Of The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Read the full pneumococcal vaccine market report here:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Geographic Regions Are Influencing Demand In The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pneumococcal Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2026, By The Business Research Company

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795